HIGHLIGHTS
- who: . and colleagues from the University of Perugia, Italy have published the research work: Farnesoid-X receptor as a therapeutic target for in ammatory bowel disease and colorectal cancer, in the Journal: (JOURNAL)
- what: The main reason is the effect of intestinal FXR-FGF15 signal. The main reason is that FXR can directly interact with NLRP3 or caspase 1 physically, frontiersin.org 10.3389/fphar.2022.1016836 kinases (MAPK)/nuclear factor u03baB (NF-u03baB) signaling pathway (Li et_al, 2019).
- how: Showed that GW4064 inhibited LPS-induced toll-like receptor 4 (TLR4)/myeloid differentiation . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.